louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03679806: Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis
Official title: Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis: Halliwick Versus Aquatic Plyometric Exercises
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis, Relapsing-Remitting
Keywords: aquatic therapy
Limits of stability
Halliwick
aquatic plyometric exercises
Lead sponsor: Dokuz Eylul University
Sponsor class: OTHER
First posted: 2018-09-20
Enrollment: 30
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare and contrast the effects of two different aquatic exercises on postural control and hand functions in people with multiple sclerosis.

Detailed description: Impaired limits of stability causes falls in people with Multiple sclerosis (pwMS) whereas a well-controlled posture provides improved upper limb functions which are limited in almost 75% of pwMS due to weakness, spasticity or tremor. It is an already known fact that hand dexterity is an indicator of fall risk due to neuromuscular causes and/or abnormalities in the corpus callosum in pwMS.

Aquatic therapy (AT) provides a safe and effective environment for many therapeutic purposes. It is important to understand the effects of each type, intensity, and duration of the aquatic interventions to accomplish most suitable aquatic exercise program.

Halliwick method, neuromotor treatment approach which uses fluid and mechanical properties of water, is based on postural control by mobilizing and controlling body parts through the Ten Point Program.

During Aquatic Plyometric Exercises, proximal part of the body needs to be stabilized to generate a sudden and powerful contraction at the distal part and stabilization of the proximal joints is necessary for maintaining distal movements in a coordinated way.

It is important to understand the effects of each type, intensity, and duration of the aquatic interventions to accomplish most suitable aquatic exercise program. This study aims to compare and contrast the effects of two different aquatic exercises on postural control and hand function.

Eligibility criteria: Inclusion Criteria:

* EDSS\>6
* volunteered

Exclusion Criteria:

* Clinical relapse within three months
* incontinence
* persistent infection

Primary outcomes:
measure: Change in limits of stability
timeFrame: Baseline and 8 weeks
measure: Change in Nine hole peg Test
timeFrame: Baseline and 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Izmir
country: Turkey
facility: Dokuz Eylul University School of Physical Therapy and Rehabilitation
Study officials:
References:
Clinical trial NCT03902106: Physiological Response to Salbutamol and Exercise
Official title: Physiological Response to Salbutamol and Exercise
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2019-04-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The scope of the study is to investigate the physiological response to salbutamol and exercise. A particular focus is on the metabolic response and amine metabolism.


Eligibility criteria: Inclusion Criteria:

* Healthy
* VO2max of \>55 ml/min/kg for men and \>50 ml/min/kg for women
* Body mass index (BMI) \< 26

Exclusion Criteria:

* Chronic use of beta2-agonist or allergy towards beta2-agonist
* Serious adverse effects to beta2-agonist
* Chronic disease deemed by the study responsible medical doctor to interfere with any part of the study
* Smoking
* Chronic use of prescription medicine deemed by the study responsible medical doctor to interfere with any part of the study
* Pregnancy (for women)

Primary outcomes:
measure: Body composition
timeFrame: Baseline, 2 weeks, 4 weeks and 6 weeks
measure: Maximal oxygen consumption (VO2max)
timeFrame: Baseline, 2 weeks, 4 weeks and 6 weeks
Secondary outcomes:
measure: Salbutamol urine concentration
timeFrame: Before (baseline) as well as 0-1 hours, 1-2 hours, 2-4 hours, 4-8 hours, and 8-16 hours after administration
Other outcomes:
measure: Muscle strength
timeFrame: Baseline, 2 weeks, 4 weeks and 6 weeks
Locations:
city: Copenhagen
country: Denmark
facility: August Krogh Building
Study officials:
References:
Clinical trial NCT00210106: Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
Official title: Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy. A Phase 2 Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Keywords: Radiofrequency ablation
Colorectal cancer
Liver metastases
Lead sponsor: Institut Bergonié
Sponsor class: OTHER
First posted: 2005-09-21
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The hypothesis is that radiofrequency ablation combined or not with resection may allow a local control (the liver) in patients suffering from unresectable colorectal liver metastases. Patients may have benefit or not from a preoperative (neoadjuvant) chemotherapy.


Eligibility criteria: Inclusion Criteria:

Colorectal cancer Hepatic metastases unresectable by classical surgery Performance status \< 2

Exclusion Criteria:

-

Primary outcomes:
measure: Complete Hepatic Response Rate at 3 Months
timeFrame: 3 months
Secondary outcomes:
measure: Overall Survival
timeFrame: at 1 and 2 years
measure: Event-free Survival
timeFrame: at 1 and 2 years
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU d'Angers
city: Angoulême
country: France
facility: Centre Saint Michel
city: Bordeaux
country: France
facility: CHU de Bordeaux
city: Bordeaux
country: France
facility: Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest
city: Clamart
country: France
facility: Hopital Béclère
city: Le Bouscat
country: France
facility: Hopital Sub-Urbain du Bouscat
city: Lyon
country: France
facility: Hopital de la Croix Rousse
city: Montpellier
country: France
facility: Hopital Saint Eloi
city: Niort
country: France
facility: Centre Hospitalier
city: Pau
country: France
facility: Centre de Radiothérapie et d'Oncologie Médicale
city: Pessac
country: France
facility: Clinique Mutualiste de Pessac
city: Périgueux
country: France
facility: Clinique Francheville
Study officials:
affiliation: Institut Bergonié
name: Serge EVRARD, Pr
role: PRINCIPAL_INVESTIGATOR
References:
citation: Evrard S, Rivoire M, Arnaud J-, Lermite E, Bellera C, Fonck M, Becouarn Y, Lalet C, Puildo M, Mathoulin-Pelissier S. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br J Surg. 2012 Apr;99(4):558-65. doi: 10.1002/bjs.8724. No abstract available.
Clinical trial NCT02305706: Right or Left for Colonoscopy?
Official title: Does Right Rather Than Left Starting Position Lead to Quicker Completion of COLonoscopy?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colonoscopy
Keywords: insertion
patient comfort
Lead sponsor: Imperial College Healthcare NHS Trust
Sponsor class: OTHER
First posted: 2014-12-03
Enrollment: 163
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Colonoscopy is technically challenging. Conventionally, colonoscopy begins with patients positioned in the left lateral position. However, few published studies have explored alternatives and there is consequently little evidence to support left lateral starting position over alternatives.

Detailed description: We aim to perform a randomised controlled trial of right versus left lateral starting position for colonoscopy. Primary outcome: time to caecum. Secondary outcomes: patient comfort; volume of sedation used.

Eligibility criteria: Inclusion Criteria:

* above 18 years of age,
* informed consent,
* routine or urgent procedures

Exclusion Criteria:

* emergency colonoscopy,
* scheduled intubation therapy

Primary outcomes:
measure: time to caecum (insertion time from rectum to caecum)
timeFrame: 30 minutes
Secondary outcomes:
measure: patient comfort (visual analogue score)
timeFrame: 5 minutes
Other outcomes:
Locations:
Study officials:
References:
citation: Vergis N, Scarborough AJ, Morris JA, Hoare JM. Prone or Left for Colonoscopy? A Randomized Controlled Trial of Prone Versus Left-sided Starting Position for Colonoscopy. J Clin Gastroenterol. 2018 Nov/Dec;52(10):e82-e86. doi: 10.1097/MCG.0000000000000871.
Clinical trial NCT00289406: Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension
Official title: An 8 Weeks, Multi-Center, Randomized, Double Blinded, Comparative Phase 3 Clinical Trial to Assess the Efficacy and Safety of S-Amlodipine Gentisate Compared to Amlodipine Besylate in Patients With Mild-to-Moderate Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension
Keywords: hypertension
Lead sponsor: SK Chemicals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2006-02-09
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to compare the antihypertensive effect and tolerability of S-amlodipine gentisate with those of amlodipine besylate in patients with mild to moderate hypertension.


Eligibility criteria: Inclusion Criteria:

* patients are required to have a mean cuff sitting diastolic blood pressure of ≥90 and ≤109 mmHg after successful completion of the 2-week placebo run-in period

Exclusion Criteria:

* any serious disorder that could limit the ability of the patient to participate in the study
* significant cardiovascular disease (angina, myocardial infarction, cerebrovascular disease, or significant arrhythmia in the preceding 6 months)
* uncontrolled diabetes mellitus (serum glucose level ≥140 mg/dl)
* insulin dependent diabetes mellitus (type I)
* secondary hypertension

Primary outcomes:
measure: The difference in mean changes from baseline in through sitting diastolic blood pressure after 8 weeks of treatment
Secondary outcomes:
measure: Mean changes in sitting systolic blood pressure; response rate (defined as the proportion of patients whose sDBP was ≤90mmHg or whose sDBP had decreased from baseline by ≥10 mmHg); changes in triglyceride and total cholesterol level of blood sample
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: SKChemicals
Study officials:
affiliation: SK Chemicals Investigational Site
name: SK Chemicals Investigational Site Seoul, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03542006: Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy
Official title: Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Central Serous Chorioretinopathy
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2018-05-31
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

Detailed description: Brinzolamide is a carbonic anhydrase inhibitor. Previously, carbonic anhydrase inhibitors have been shown to be effective for the treatment of macular edema when administered orally, also for central serous chorioretinopathy. However, this treatment carries the risk of severe side effects.

The goal of this study is to examine the efficacy of the topical form of treatment of carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous chorioretinopathy.

Eligibility criteria: Inclusion Criteria:

* Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4 months of follow-up
* Optical coherence tomography (OCT) shows foveal subretinal fluid
* Fluorescein angiography and indocyanine green confirm the diagnosis

Exclusion Criteria:

* Any other ophthalmic condition that may lead to subretinal fluid
* Choroidal neovascularization
* Myopia \> -6D
* Previous treatment for CSC in the past 6 months
* Known allergy to fluorescein or indocyanin green
* Known allergy for brinzolamide
* Pregnancy, breast feeding

Primary outcomes:
measure: Change in subretinal fluid (microns)
timeFrame: 6 months
Secondary outcomes:
measure: Change in ETDRS visual acuity (number of letters)
timeFrame: 6 months
measure: Change in central macular thickness (microns)
timeFrame: 6 months
measure: Change in choroidal thickness (microns)
timeFrame: 6 months
measure: Time for fluid resolution (days)
timeFrame: 6 months
measure: Percentage of patients with fluid resolution
timeFrame: 6 months
measure: Quality of life assessment (using NEI-VFQ-25 questionnaires)
timeFrame: 6 months
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
facility: Iglicki Oftalmologia
city: Tel Aviv
country: Israel
facility: Tel Aviv Medical Center
Study officials:
affiliation: Tel-Aviv Sourasky Medical Center
name: Dinah Zur
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05407506: Clinical Study of Ultrasonic Artificial Intelligence and Fine Needle Aspiration in Qualitative Diagnosis of Thyroid Nodules
Official title: Clinical Study of Ultrasonic Artificial Intelligence and Fine Needle Aspiration in Qualitative Diagnosis of Thyroid Nodules
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Thyroid Nodule
Lead sponsor: Zhejiang University
Sponsor class: OTHER
First posted: 2022-06-07
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To study the value of thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules, so as to provide evidence-based medical evidence for the diagnosis of benign and malignant thyroid nodules by artificial intelligence.


Eligibility criteria: Inclusion Criteria:

* (1) Age 18-75 years old, regardless of gender; (2) The nodules were observed with complete transverse and longitudinal standard sections; (3) The nodules were observed and underwent thyroid fine needle aspiration, including cytology and BRAF gene mutation detection; (4) Patients voluntarily entered the study after informed consent.

Exclusion Criteria:

* (1) If the observed nodule is less than 2mm or more than 50mm, the artificial intelligence system cannot recognize it; (2) Uncontrolled subacute thyroiditis and hyperthyroidism; (3) Previous thyroid surgery or radiofrequency ablation of thyroid nodules; (4) History of neck trauma.

Primary outcomes:
measure: THYROID AI
timeFrame: immediately after the procedure
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: First People's Hospital of Hangzhou
name: Dingcun Luo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00776906: Advance® 18PTX® Balloon Catheter Study
Official title: Advance® 18PTX® Balloon Catheter Study: Treatment of Lesions in Superficial Femoral Artery/Popliteal Artery With a Paclitaxel-coated Balloon
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Cook Group Incorporated
Sponsor class: INDUSTRY
First posted: 2008-10-22
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Advance® 18 PTX® Balloon Catheter study is a clinical trial to study the safety and effectiveness of the Advance 18® PTX® Balloon Catheter in the treatment of lesions in the superficial femoral artery and popliteal artery.


Eligibility criteria: Key Inclusion Criteria:

* Age \>18 years.
* Able to provide informed consent.
* Has at least one de novo or restenotic lesion(s) with \> 70% stenosis documented angiographically of the SFA or popliteal artery. If more than one lesion requires intervention, only one should be treated as a study lesion.

Key Exclusion Criteria:

* Has significant stenosis (\> 50%) or occlusion of inflow tract (proximal ipsilateral, iliofemoral, or aortic lesions) not successfully treated before this procedure.
* Lack of at least one patent runoff vessel with \< 50% stenosis throughout its course.
* Lesions in target area requiring atherectomy (or ablative devices), cutting balloons, cryoplasty balloons, or any other advanced device to facilitate angioplasty balloon or stent delivery.

Primary outcomes:
measure: Evaluation of Late Lumen Loss
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Leipzig
country: Germany
facility: Heart Center Leipzig/Park Hospital
city: Rosenheim
country: Germany
facility: Klinikum Rosenheim
city: Tubingen
country: Germany
facility: Universitat Klinik Tubingen
city: Moscow
country: Russian Federation
facility: Endosurgery and Lithotripsy Center
Study officials:
References:
Clinical trial NCT03191006: Effects of Insoles on Children With Developmental Delays
Official title: Therapeutic Effects of Physical Function and Balance of Customized Insoles on Children With Developmental Delays
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Developmental Delay
Keywords: effect
insoles
children
Lead sponsor: Taipei Medical University
Sponsor class: OTHER
Collaborators: name: Shin Kong Wu Ho-Su Memorial Hospital
First posted: 2017-06-19
Enrollment: 52
Sex: ALL
Minimum age (years): 3
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Using double blind, randomized controlled design to investigate the short-term therapeutic effects of function of customized insoles on children with developmental delays

Detailed description: A total of 52 children with developmental delays will be enrolled. The participants will be randomized into two groups, including study group (with insoles) and control group (without insoles).

The participants in the study group will be evaluated at baseline, that is before the customized insoles are prescribed. All of evaluations, including physical function, balance, and quality of life will be re-evaluated up to 12 weeks after insoles wearing.

The control group will be evaluated at the baseline and up to 12 weeks.

Eligibility criteria: Inclusion Criteria:

* developmental delays

Exclusion Criteria:

* age less than 3 years old or older than 10 years old normal development

Primary outcomes:
measure: change from baseline functional performance (scores) at 12 weeks
timeFrame: baseline and up to 12 weeks
Secondary outcomes:
measure: change from baseline physical function (time) at 12 weeks
timeFrame: baseline and up to 12 weeks
measure: change from baseline balance (scores) at 12 weeks
timeFrame: baseline and up to 12 weeks
measure: change from baseline quality of life at 12 weeks
timeFrame: baseline and up to 12 weeks
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Shin Kong Wu Ho-Su Memorial Hospital
Study officials:
affiliation: Shin Kong Wu Ho-Su Memorial Hospital; Taipei Medical University
name: Ru-Lan Hsieh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03414606: Social Behavior in Depression
Official title: Social Behavior in Depression
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Depression
Lead sponsor: Beijing Normal University
Sponsor class: OTHER
Collaborators: name: Huilongguan Hospital
First posted: 2018-01-30
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals diagnosed with depression and healthy control

Brief summary: In the project, investigators basically plan to test the difference in social behavior and social cognition between depressive patients and healthy individuals. To test this, investigators plan to use traditional or novel behavioral experiment paradigms to target various behaviors.


Eligibility criteria: Inclusion Criteria:

* Age range between 18 and 60
* Education experience above high school
* Score for Hamilton's Depression Scale \>=17
* Diagnosis of depression through Scid

Exclusion Criteria:

* Undergoing electric shock treatment in 3 months
* Excluding those who with bipolar disorder
* Excluding those who with postpartum depression
* Excluding those who with hysteria

Primary outcomes:
measure: Prosocial behavior
timeFrame: Baseline
measure: Cognitive flexibility
timeFrame: Baseline
measure: Valuation of social information
timeFrame: Baseline
measure: Optimism bias
timeFrame: Baseline
measure: Emotion recognition
timeFrame: Baseline
measure: Model-free & model-based tendency
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Huilongguan Hospital
Study officials:
affiliation: Beijing Normal University
name: Yina Ma, Doctor
role: STUDY_CHAIR
References: